



Thrombotic  microangiopathy  coming  of age
Thrombotic  microangiopathy  (TM) is  characterized  by
the  presence  of  thrombocytopenia  and  microangiopathic
hemolytic  anemia.  There are  different  pathologies  of  var-
ious  etiologies,  hereditary  or  acquired,  which  causes  said
microangiopathy.  A prompt  diagnosis  is  of the  utmost  impor-
tance  in  order  to begin  treatment  immediately,  since  this
pathology  is  considered  a  medical  emergency.
Classic  TM,  thrombocytopenic  thrombotic  purpura  (TTP),
is  caused  by  a  severe  ADAMTS-13  deficiency  (disintegrin
and  metalproteinase),  acquired  mostly  by autoantibodies,
this  enzyme  normally  proteolizes  native  von  Willebrand
factor  immediately  after  being  synthesized  in the vascu-
lar  endothelium  generating  the  normal  multimers,  which
are  the  physiological  active molecules  leading  to  platelet
adherence  and  aggregation  as  part  of  normal thrombus  for-
mation.  Atypical  hemolytic  uremic  syndrome  (aHUS)  is  very
similar  to TTP,  although  it is  linked  to  genetic  defects.1
In  the  last  decade,  management,  diagnosis  and  treatment
of these  pathologies  have  evolved  notably.  Téllez-Hinojosa
et  al.2 elegantly  analyzes  classic  TM  etiopathogenesis,
diagnosis  and  treatment  in  this  issue  of  Medicina  Uni-
versitaria.  It is  very  important  to  insist  that  a timely
diagnosis  is mandatory  in  order  to  procede  to  a rapid
therapeutic  intervention  (plasma  exchange),  which  can be
life-saving.  In  this  respect,  the examination  of  a  well-stained
peripheral  blood  slide  by  an experimented  hematologist
is  critical  in  establishing  the presence  of  this  hematolog-
ical  emergency,  requiring  a  multidisciplinary  therapeutic
approach.
Refractory  TTP  treatment  has evolved  considerably;
the  role  of  splenectomy  in patients  who  do  not respond
to  rituximab  has  been  described  with  a relapse-free
survival  rate  of  70%  at 10  years.  The  use  of  bortezomib,
cyclosporine,  cyclophosphamide,  vincristine,  eculizumab
and  N-acetylcysteine  have  been reported  in  some  refrac-
tory  cases  as  multiple  first  and  second  line  therapies,  with
different  responses.3
TTP diagnosis  will  have  to  be more  precise.  ADAMTS-13
activity  determination  has  been  relevant  in the study  of TTP
pathogenesis;  however,  it does  not  identify  all patients  who
benefit  from  plasma  exchange.4 The  treatment  will have
to  be more  effective,  more  accessible  and  safer.  Survival
rate  has not  improved  substantially  since  the  introduction
of  plasmapheresis,  which is  technically  complex,  expen-
sive  and  may  cause  complications.  Significant  advances  have
been  made  in  the  study  of  TTP;  nevertheless,  there  is  still
much  more  to  be accomplished.
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